The future of the global induced pluripotent stem cell market looks promising with opportunities in the research & academic institute, biotechnology & pharmaceutical company, and hospital & clinic markets. The global induced pluripotent stem cell market is expected to reach an estimated $2.6 billion by 2030 with a CAGR of 10.3% from 2024 to 2030. The major drivers for this market are rising prevalence of cancer, amplified financial investments in stem cell research, and the numerous benefits of induced pluripotent stem cells (iPSCs) compared to embryonic stem cells (ESCs).
Some of the key questions
answered in this exclusive report are:
Q.1. What are some of
the most promising, high-growth opportunities for the induced pluripotent stem
cell market by workflow (reprogramming, cell culture, cell characterization /
analysis, engineering, and others), application (drug development &
discovery, regenerative medicine, toxicology studies, and others), end use
(research & academic institutes, biotechnology & pharmaceutical
companies, and hospitals & clinics), and region (North America, Europe,
Asia Pacific, and the Rest of the World)?
Q.2. Which segments will
grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and
why?
Q.4. What are the key
factors affecting market dynamics? What are the key challenges and business
risks in this market?
Q.5. What are the
business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market
and the reasons behind them?
Q.7. What are some of
the changing demands of customers in the market?
Q.8. What are the new
developments in the market? Which companies are leading these developments?
Q.9. Who are the major
players in this market? What strategic initiatives are key players pursuing for
business growth?
Q.10. What are some of
the competing products in this market and how big of a threat do they pose for
loss of market share by material or product substitution?
Q.11. What M&A
activity has occurred in the last 5 years and what has its impact been on the
industry?
Market Segmentation:
In this market, drug
development & discovery, regenerative medicine, and toxicology studies are
the major segments of induced pluripotent stem cell market by application.
Lucintel forecasts that drug development & discovery will remain the
largest segment over the forecast period because the chronic illnesses are
spreading throughout the world.
Within this market,
biotechnology & pharmaceutical companies will remain the largest segment
over the forecast period due to the accessibility and utilization of a wide
range of kits, consumables, and instruments in conjunction with iPSC products.
APAC is expected to
witness fastest growth over the forecast period due to robust, cost-effective
focus on stem cell-based research, the expansion of economies, improvements in
healthcare strategies, and the increasing recognition of the promise of
personalized treatments.
Lonza, Axol Bioscience,
Evotec, Hitachi, Reprocell, Merck, Reprocells, Fate Therapeutics, Thermo Fisher
Scientific, and Stemcellsfactory III are the major suppliers in the induced
pluripotent stem cell market.
About
Lucintel
Lucintel, the premier global
management consulting and market research firm, creates winning strategies for
growth. It offers market assessments, competitive analysis, opportunity
analysis, growth
consulting, M&A, and due diligence services to executives and
key decision-makers in a variety of industries.
Contact:
Roy Almaguer
Lucintel
Dallas, Texas, USA
Email: roy.almaguer@lucintel.com
Tel. 972.636.5056
Related Reports
1. Pharmaceutical Contract Manufacturing Market
3. Stent Market
5. 3D
Printing Medical Device Market
8. Medical Lifting Sling
Market
10. Stretcher Market
No comments:
Post a Comment